amsacrine has been researched along with Leukemia in 100 studies
Amsacrine: An aminoacridine derivative that intercalates into DNA and is used as an antineoplastic agent.
amsacrine : A sulfonamide that is N-phenylmethanesulfonamide substituted by a methoxy group at position 3 and an acridin-9-ylamino group at position 4. It exhibits antineoplastic activity.
Leukemia: A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)
| Excerpt | Relevance | Reference |
|---|---|---|
| " The side effects and toxicity of the amsacrine-based regimen were similar to that of other antileukemia regimens." | 9.08 | [Phase III clinical trial on domestic amsacrine in patients with acute leukemias]. ( , 1997) |
| "The combination of high-dose cytarabine (ara-C) and amsacrine (m-AMSA) is effective treatment for relapsed adult acute leukemia." | 9.06 | Effect of amsacrine on ara-CTP cellular pharmacology in human leukemia cells during high-dose cytarabine therapy. ( Keating, MJ; Nowak, B; Plunkett, W, 1987) |
| "Amsacrine and high-dose cytarabine (HiDAc), when administered as single agents, are effective treatment of acute leukemia." | 9.06 | A new regimen of amsacrine with high-dose cytarabine is safe and effective therapy for acute leukemia. ( Ahmed, T; Arlin, ZA; Baskind, P; Feldman, E; Mehta, R; Mittelman, A; Rieber, E; Sullivan, P; Weinstein, P, 1987) |
| "This study explores the suppression mechanism of amsacrine (4-(9-Acridinylamino)-N-(methanesulfonyl)-m-anisidine hydrochloride) on matrix metalloproteinase-2 (MMP-2) and MMP-9 expression in human leukemia cells." | 7.80 | Amsacrine suppresses matrix metalloproteinase-2 (MMP-2)/MMP-9 expression in human leukemia cells. ( Chang, LS; Chen, YJ; Chien, JH; Liu, WH, 2014) |
| "Amsacrine (AMSA) was a high effective medicine of acute leukemia treatment." | 7.69 | [Venous protection of acute leukemia treatment with amsacrine]. ( Hong, J; Ma, XJ; Xiang, YM, 1996) |
| "The role of amsacrine in inducing remission in patients with cardiac disease and acute leukemia was evaluated." | 7.68 | Amsacrine is safe and effective therapy for patients with myocardial dysfunction and acute leukemia. ( Ahmed, T; Arlin, ZA; Baskind, P; Chun, HG; Cook, P; Feldman, EJ; Marboe, C; Mehta, R; Mittelman, A; Puccio, C, 1991) |
| "The antileukemia drug amsacrine and seven analogues were tested for in vitro activity against five multidrug-resistant human leukemia cell sublines (two derived from each of two Jurkat parent lines and one from the K562 line) and the corresponding parent lines (Jurkat, K562, and P388 leukemia)." | 7.68 | Multiple patterns of resistance of human leukemia cell sublines to amsacrine analogues. ( Baguley, BC; Finlay, GJ; Judd, W; Snow, K, 1990) |
| "The characterization of type II topoisomerases from amsacrine-sensitive (HL-60) and amsacrine-resistant (HL-60/AMSA) human leukemia cells was extended." | 7.68 | Further characterization of an amsacrine-resistant line of HL-60 human leukemia cells and its topoisomerase II. Effects of ATP concentration, anion concentration, and the three-dimensional structure of the DNA target. ( Altschuler, E; Hinds, M; Kim, P; Mayes, J; Soares, L; Zwelling, LA, 1993) |
| "Twenty-two evaluable adult patients with relapsed, acute nonlymphocytic leukemia (ANLL) were treated with the combination of amsacrine (m-AMSA) and 5-azacytidine (AZA) as part of an Eastern Cooperative Oncology Group (ECOG) pilot study to evaluate efficacy and toxicity." | 7.67 | Amsacrine [4'-(9-acridinylamino)-methanesulfon-m-anisidide] (m-AMSA) and 5-azacytidine (AZA) for remission reinduction in patients with relapsed adult acute nonlymphocytic leukemia. An ECOG pilot study. Eastern Cooperative Oncology Group. ( Glick, JH; Kahn, SB; Knospe, WH; Soojian, M; Spiers, A, 1987) |
| "Fourteen patients with refractory acute non-lymphocytic leukemia were entered into a dose-seeking trial of combination therapy with etoposide and amsacrine given daily for five consecutive days." | 7.67 | Phase I study of VP-16 (etoposide) and amsacrine (AMSA) in the treatment of refractory acute leukemia. ( Hinemann, V; Hoagland, HC; Kovach, JS; Letendre, L, 1985) |
| "Amsacrine (AMSA) has been shown to be an effective therapeutic agent in the treatment of adult acute nonlymphocytic leukemia (ANLL)." | 7.67 | High-dose amsacrine (AMSA) therapy of relapsed and refractory adult acute nonlymphocytic leukemia. A phase II study. ( Bennett, JM; Cassileth, PA; Glick, JH; Lyman, GH; Oken, MM, 1984) |
| "The authors report a case of focal myocardial necrosis, presenting clinically as an acute myocardial infarction during the administration of the antineoplastic drug, amsacrine, in a patient without coronary artery disease." | 7.67 | Acute myocardial necrosis during administration of amsacrine. ( Burns, CP; Lindpaintner, K; Lindpaintner, LS; Wentworth, M, 1986) |
| "In order to test the toxicity and efficacy of intensive postremission therapy with high-dose cytosine arabinoside with L-asparaginase and amsacrine with etoposide in adults with acute nonlymphocytic leukemia (ANL), 100 adults (ages 19 to 75) with previously untreated ANL were entered into a study using six sequential cycles of chemotherapy." | 7.67 | Evaluation of intensive postremission chemotherapy for adults with acute nonlymphocytic leukemia using high-dose cytosine arabinoside with L-asparaginase and amsacrine with etoposide. ( Amos, D; Appelbaum, FR; Goldberg, RS; Livingston, RB; Mortimer, J; Tallman, MS; Thomas, ED; Weiden, PL, 1987) |
| "We varied the number of doses of high-dose cytarabine (3 g/m2) given to patients with acute leukemia in relapse who were receiving therapeutic doses of amsacrine (600 mg/m2/course)." | 7.67 | Treatment of acute leukemia with amsacrine and high-dose cytarabine. ( Ahmed, T; Arlin, ZA; Friedland, M; Gaddipati, J; Mittelman, A; Rieber, E, 1985) |
| "Thirteen patients (7 male, 9 female) aged 22-71 years (means = 55 years) with acute non-lymphocytic leukemia and contraindications for anthracyclin therapy were treated with combined chemotherapy using m-amsacrine primarily or in relapse." | 7.67 | Combined chemotherapy with m-amsacrine in high-risk patients with acute non-lymphocytic leukemia. ( Hiddemann, W; Kreutzmann, H; Maschmeyer, G; Wendt, F, 1987) |
| "Twenty-six adults with refractory leukemia were treated with amsacrine gluconate, a new formulation." | 7.66 | Phase II study of amsacrine gluconate in refractory leukemia. ( Grillo-Lopez, AJ; Omura, GA; Vogler, WR; Winton, EF; Zuckerman, KS, 1983) |
| " The side effects and toxicity of the amsacrine-based regimen were similar to that of other antileukemia regimens." | 5.08 | [Phase III clinical trial on domestic amsacrine in patients with acute leukemias]. ( , 1997) |
| "The combination of high-dose cytarabine (ara-C) and amsacrine (m-AMSA) is effective treatment for relapsed adult acute leukemia." | 5.06 | Effect of amsacrine on ara-CTP cellular pharmacology in human leukemia cells during high-dose cytarabine therapy. ( Keating, MJ; Nowak, B; Plunkett, W, 1987) |
| "This clinical trial (DT7995) was designed to evaluate amsacrine (AMSA) plus cytosine arabinoside (ara-C), vincristine, and prednisone (OAP) therapy in previously untreated patients with adult acute leukemia and to investigate a new strategy for assignment of patients to treatment using estimated probabilities of complete remission (PPR) based on six prognostic factors." | 5.06 | A strategy for evaluation of new treatments in untreated patients: application to a clinical trial of AMSA for acute leukemia. ( Estey, EH; Freireich, EJ; Gehan, EA; Kantarjian, HM; Keating, MJ; McCredie, KB; Smith, TL; Walters, RS, 1987) |
| "Amsacrine and high-dose cytarabine (HiDAc), when administered as single agents, are effective treatment of acute leukemia." | 5.06 | A new regimen of amsacrine with high-dose cytarabine is safe and effective therapy for acute leukemia. ( Ahmed, T; Arlin, ZA; Baskind, P; Feldman, E; Mehta, R; Mittelman, A; Rieber, E; Sullivan, P; Weinstein, P, 1987) |
| "Amsacrine is an antileukemia drug being widely used in North America, Europe, Australia, and New Zealand." | 5.06 | Amsacrine-associated cardiotoxicity: an analysis of 82 cases. ( Grillo-López, AJ; Hess, F; Marsoni, S; Posada, JG; Ross, BJ; Weiss, RB, 1986) |
| "This study explores the suppression mechanism of amsacrine (4-(9-Acridinylamino)-N-(methanesulfonyl)-m-anisidine hydrochloride) on matrix metalloproteinase-2 (MMP-2) and MMP-9 expression in human leukemia cells." | 3.80 | Amsacrine suppresses matrix metalloproteinase-2 (MMP-2)/MMP-9 expression in human leukemia cells. ( Chang, LS; Chen, YJ; Chien, JH; Liu, WH, 2014) |
| " The single-arm trial evaluated amsacrine plus cytosine arabinoside, vincristine, and prednisone (a combination abbreviated as OAP) for adult acute leukemia, when standard treatment was adriamycin plus OAP." | 3.75 | Treatment-subgroup interaction: an example from a published, phase II clinical trial. ( Behrendt, CE; Gehan, EA, 2009) |
| "Amsacrine (AMSA) was a high effective medicine of acute leukemia treatment." | 3.69 | [Venous protection of acute leukemia treatment with amsacrine]. ( Hong, J; Ma, XJ; Xiang, YM, 1996) |
| "The antileukemia drug amsacrine and seven analogues were tested for in vitro activity against five multidrug-resistant human leukemia cell sublines (two derived from each of two Jurkat parent lines and one from the K562 line) and the corresponding parent lines (Jurkat, K562, and P388 leukemia)." | 3.68 | Multiple patterns of resistance of human leukemia cell sublines to amsacrine analogues. ( Baguley, BC; Finlay, GJ; Judd, W; Snow, K, 1990) |
| "The role of amsacrine in inducing remission in patients with cardiac disease and acute leukemia was evaluated." | 3.68 | Amsacrine is safe and effective therapy for patients with myocardial dysfunction and acute leukemia. ( Ahmed, T; Arlin, ZA; Baskind, P; Chun, HG; Cook, P; Feldman, EJ; Marboe, C; Mehta, R; Mittelman, A; Puccio, C, 1991) |
| "The coumermycin antibiotic novobiocin, which interacts with the nuclear enzyme topoisomerase II, produced supra-additive toxicity to WEHI-3B D+ leukemia cells at clinically achievable concentrations, when combined with teniposide (VM-26) or etoposide (VP-16)." | 3.68 | Potentiation by novobiocin of the cytotoxic activity of etoposide (VP-16) and teniposide (VM-26). ( Lorico, A; Rappa, G; Sartorelli, AC, 1992) |
| "The characterization of type II topoisomerases from amsacrine-sensitive (HL-60) and amsacrine-resistant (HL-60/AMSA) human leukemia cells was extended." | 3.68 | Further characterization of an amsacrine-resistant line of HL-60 human leukemia cells and its topoisomerase II. Effects of ATP concentration, anion concentration, and the three-dimensional structure of the DNA target. ( Altschuler, E; Hinds, M; Kim, P; Mayes, J; Soares, L; Zwelling, LA, 1993) |
| "Twenty-two evaluable adult patients with relapsed, acute nonlymphocytic leukemia (ANLL) were treated with the combination of amsacrine (m-AMSA) and 5-azacytidine (AZA) as part of an Eastern Cooperative Oncology Group (ECOG) pilot study to evaluate efficacy and toxicity." | 3.67 | Amsacrine [4'-(9-acridinylamino)-methanesulfon-m-anisidide] (m-AMSA) and 5-azacytidine (AZA) for remission reinduction in patients with relapsed adult acute nonlymphocytic leukemia. An ECOG pilot study. Eastern Cooperative Oncology Group. ( Glick, JH; Kahn, SB; Knospe, WH; Soojian, M; Spiers, A, 1987) |
| "The ability of a noncytotoxic dose of ara-C to modulate the amount of 4'-(9-acridinylamino)-methanesulfon-m-anisidide (m-AMSA)- or etoposide-induced topoisomerase II-mediated DNA cleavage and cytotoxicity was examined in m-AMSA-sensitive and -resistant HL-60 human leukemia cells." | 3.67 | Effect of 1-beta-D-arabinofuranosylcytosine (ara-C) on nuclear topoisomerase II activity and on the DNA cleavage and cytotoxicity produced by 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA) and etoposide in m-AMSA-sensitive and -resistant human le ( Andersson, BS; Bakic, M; Beran, M; Chan, D; Estey, E; Ricketts, L; Silberman, L; Zwelling, LA, 1987) |
| "Thirteen patients (7 male, 9 female) aged 22-71 years (means = 55 years) with acute non-lymphocytic leukemia and contraindications for anthracyclin therapy were treated with combined chemotherapy using m-amsacrine primarily or in relapse." | 3.67 | Combined chemotherapy with m-amsacrine in high-risk patients with acute non-lymphocytic leukemia. ( Hiddemann, W; Kreutzmann, H; Maschmeyer, G; Wendt, F, 1987) |
| "The ECG effect of amsacrine (m-AMSA) was evaluated in 12 consecutive patients with leukemia." | 3.67 | Acute electrocardiographic changes induced by amsacrine. ( Hasin, Y; Shinar, E, 1984) |
| "The authors report a case of focal myocardial necrosis, presenting clinically as an acute myocardial infarction during the administration of the antineoplastic drug, amsacrine, in a patient without coronary artery disease." | 3.67 | Acute myocardial necrosis during administration of amsacrine. ( Burns, CP; Lindpaintner, K; Lindpaintner, LS; Wentworth, M, 1986) |
| "In order to test the toxicity and efficacy of intensive postremission therapy with high-dose cytosine arabinoside with L-asparaginase and amsacrine with etoposide in adults with acute nonlymphocytic leukemia (ANL), 100 adults (ages 19 to 75) with previously untreated ANL were entered into a study using six sequential cycles of chemotherapy." | 3.67 | Evaluation of intensive postremission chemotherapy for adults with acute nonlymphocytic leukemia using high-dose cytosine arabinoside with L-asparaginase and amsacrine with etoposide. ( Amos, D; Appelbaum, FR; Goldberg, RS; Livingston, RB; Mortimer, J; Tallman, MS; Thomas, ED; Weiden, PL, 1987) |
| "Thirty-five adults with acute nonlymphocytic leukemia who were in complete remission after initial induction therapy received a single course of high-dose cytarabine and amsacrine as consolidation therapy." | 3.67 | Prolonged unmaintained remission after intensive consolidation therapy in adult acute nonlymphocytic leukemia. ( Begg, CB; Bennett, JM; Burkart, PT; Cassileth, PA; Knospe, WH; Mazza, JJ; Oken, MM; Scharfman, W; Silber, R; Spiers, A, 1987) |
| "Fourteen patients with refractory acute non-lymphocytic leukemia were entered into a dose-seeking trial of combination therapy with etoposide and amsacrine given daily for five consecutive days." | 3.67 | Phase I study of VP-16 (etoposide) and amsacrine (AMSA) in the treatment of refractory acute leukemia. ( Hinemann, V; Hoagland, HC; Kovach, JS; Letendre, L, 1985) |
| "Amsacrine (AMSA) has been shown to be an effective therapeutic agent in the treatment of adult acute nonlymphocytic leukemia (ANLL)." | 3.67 | High-dose amsacrine (AMSA) therapy of relapsed and refractory adult acute nonlymphocytic leukemia. A phase II study. ( Bennett, JM; Cassileth, PA; Glick, JH; Lyman, GH; Oken, MM, 1984) |
| "We varied the number of doses of high-dose cytarabine (3 g/m2) given to patients with acute leukemia in relapse who were receiving therapeutic doses of amsacrine (600 mg/m2/course)." | 3.67 | Treatment of acute leukemia with amsacrine and high-dose cytarabine. ( Ahmed, T; Arlin, ZA; Friedland, M; Gaddipati, J; Mittelman, A; Rieber, E, 1985) |
| "Among new drugs being studied currently, AMSA and mitoxantrone have shown significant usefulness against acute non-lymphocytic leukemia in adults." | 3.67 | [A new drug and current strategy in the treatment of acute non-lymphocytic leukemia in adults]. ( Ogawa, M, 1986) |
| "Twenty-six adults with refractory leukemia were treated with amsacrine gluconate, a new formulation." | 3.66 | Phase II study of amsacrine gluconate in refractory leukemia. ( Grillo-Lopez, AJ; Omura, GA; Vogler, WR; Winton, EF; Zuckerman, KS, 1983) |
| "m-AMSA is a new drug in the National Cancer Institute Drug Development Program." | 2.65 | m-AMSA: an exciting new drug in the National Cancer Institute Drug Development Program. ( Charles, LM; Macdonald, JS; Weiss, RB, 1980) |
| "Bacterial or fungal infections (considered life-threatening or fatal) occurred in 17 children with ALL and in 7 with ANLL." | 2.65 | Evaluation of AMSA in children with acute leukemia. A Pediatric Oncology Group study. ( Civin, CI; Frankel, LS; Krischer, J; Land, VJ; Mahoney, DH; Ragab, AH, 1984) |
| "The sinusitis was successfully treated with AmBisome, and surgical debridement." | 1.33 | Zygomycosis in the immunocompromised patient: a case report. ( Aoun, M; Beguin, H; Georgala, A; Husson, M; Meuleman, N; Nolard, N; Vekemans, M, 2006) |
| " push in a dosage of 150 mg/m2 for 5 days." | 1.27 | 4'-(9-acridinylamino)methane-sulfon-m-anisidide (m-AMSA) and 5-azacytidine (AZA) in the treatment of relapsed adult acute leukemia. ( Brodsky, I; Bulova, S; Conroy, JF; Kahn, SB; Lebedda, J; Sklaroff, R, 1983) |
| "A pharmacokinetic study was performed in 13 adult patients with acute nonlymphoblastic leukemia to compare two formulations of 4'-(9-acridinylamino)-methanesulphone-m-ansidide (AMSA): the original formulation, AMSA-NCL, and a water-soluble lyophilized formulation, AMSA-lactate (Bristol Myers, Syracuse, N." | 1.27 | Comparison of the pharmacokinetics of AMSA and AMSA-lactate in patients with acute nonlymphoblastic leukemia. ( Farmen, RH; Franks, CR; Liliemark, JO; Paul, CY; Peterson, CO; Uytdenhoef, M, 1987) |
| "Hyperbilirubinemia was seen in 25% of the patients treated." | 1.26 | Phase I and II trial of 4'-(9-acridinylamino)methanesulfon-m-anisidide in patients with acute leukemia. ( Arlin, ZA; Clarkson, BD; Gee, TS; Howard, J; Kempin, SJ; Sklaroff, RB; Young, CW, 1980) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 71 (71.00) | 18.7374 |
| 1990's | 22 (22.00) | 18.2507 |
| 2000's | 5 (5.00) | 29.6817 |
| 2010's | 1 (1.00) | 24.3611 |
| 2020's | 1 (1.00) | 2.80 |
| Authors | Studies |
|---|---|
| Spicer, JA | 1 |
| Gamage, SA | 1 |
| Atwell, GJ | 1 |
| Finlay, GJ | 4 |
| Baguley, BC | 7 |
| Denny, WA | 1 |
| Kolb, HJ | 1 |
| Schmid, C | 1 |
| Liu, WH | 1 |
| Chen, YJ | 1 |
| Chien, JH | 1 |
| Chang, LS | 1 |
| Behrendt, CE | 1 |
| Gehan, EA | 2 |
| Tauro, S | 1 |
| Shankaranarayana, P | 1 |
| Nitu-Whalley, IC | 1 |
| Duncan, N | 1 |
| Begum, G | 1 |
| Craig, JI | 1 |
| Marcus, RE | 1 |
| Craddock, CF | 1 |
| Mahendra, P | 1 |
| Boutonnat, J | 1 |
| Faussat, AM | 1 |
| Marie, JP | 1 |
| Bignon, J | 1 |
| Wdzieczak-Bakala, J | 1 |
| Barbier, M | 1 |
| Thierry, J | 1 |
| Ronot, X | 1 |
| Colle, PE | 1 |
| Georgala, A | 1 |
| Vekemans, M | 1 |
| Husson, M | 1 |
| Meuleman, N | 1 |
| Beguin, H | 1 |
| Nolard, N | 1 |
| Aoun, M | 1 |
| Carella, AM | 1 |
| Santini, G | 1 |
| Marmont, AM | 1 |
| Miller, LP | 1 |
| Miller, DR | 2 |
| Tan, CT | 2 |
| Kahn, SB | 2 |
| Sklaroff, R | 1 |
| Lebedda, J | 1 |
| Conroy, JF | 1 |
| Bulova, S | 1 |
| Brodsky, I | 1 |
| Gahrton, G | 1 |
| Hines, JD | 3 |
| Oken, MM | 5 |
| Mazza, JJ | 4 |
| Keller, AM | 1 |
| Streeter, RR | 1 |
| Glick, JH | 3 |
| Arlin, ZA | 9 |
| Carter, SK | 1 |
| Naparstek, E | 1 |
| Shinar, E | 2 |
| Polliack, A | 1 |
| Cassileth, PA | 2 |
| Lyman, GH | 1 |
| Bennett, JM | 4 |
| Omura, GA | 1 |
| Winton, EF | 1 |
| Vogler, WR | 1 |
| Zuckerman, KS | 1 |
| Grillo-Lopez, AJ | 2 |
| Estey, EH | 2 |
| Keating, MJ | 5 |
| Smith, TL | 2 |
| McCredie, KB | 7 |
| Legha, SS | 4 |
| Walters, RS | 2 |
| Bodey, GP | 4 |
| Freireich, EJ | 4 |
| Krischer, J | 1 |
| Land, VJ | 1 |
| Civin, CI | 1 |
| Ragab, AH | 1 |
| Mahoney, DH | 1 |
| Frankel, LS | 1 |
| Case, DC | 1 |
| Hasin, Y | 1 |
| Mittelman, A | 4 |
| Zander, AR | 1 |
| Vellekoop, L | 1 |
| Dicke, KA | 1 |
| Spitzer, G | 1 |
| Verma, D | 1 |
| Check, WA | 1 |
| Goldsmith, MA | 1 |
| Bhardwaj, S | 1 |
| Ohnuma, T | 1 |
| Greenspan, EM | 1 |
| Holland, JF | 1 |
| Flomenberg, N | 1 |
| Gee, TS | 2 |
| Kempin, SJ | 2 |
| Dellaquila, C | 1 |
| Mertelsmann, R | 1 |
| Straus, DJ | 1 |
| Young, CW | 2 |
| Clarkson, BD | 2 |
| Hancock, C | 1 |
| Steinherz, PG | 1 |
| Steinherz, LJ | 1 |
| Sorell, M | 1 |
| Chan, KW | 1 |
| Mondora, A | 1 |
| Mahal, PS | 1 |
| Valdivieso, M | 1 |
| Luna, M | 1 |
| Benjamin, RS | 1 |
| Ahmann, FR | 1 |
| Meyskens, FL | 1 |
| Moon, TE | 1 |
| Durie, BG | 1 |
| Salmon, SE | 1 |
| Horikoshi, N | 1 |
| Ogawa, M | 2 |
| Inagaki, J | 1 |
| Ezaki, K | 1 |
| Inoue, K | 1 |
| Okabe, K | 1 |
| Nagata, T | 1 |
| Aiba, K | 1 |
| Domyo, M | 1 |
| Sklaroff, RB | 1 |
| Howard, J | 1 |
| Fanucchi, MP | 1 |
| Macdonald, JS | 2 |
| Marsoni, S | 2 |
| Bruno, S | 1 |
| Poster, D | 1 |
| Weiss, RB | 2 |
| Charles, LM | 1 |
| Lawrence, HJ | 1 |
| Ries, CA | 1 |
| Reynolds, RD | 1 |
| Lewis, JP | 1 |
| Koretz, MM | 1 |
| Torti, FM | 1 |
| Boege, F | 2 |
| Biersack, H | 2 |
| Meyer, P | 2 |
| Ellis, AL | 1 |
| Nowak, B | 2 |
| Plunkett, W | 3 |
| Zwelling, LA | 7 |
| Mayes, J | 3 |
| Hinds, M | 3 |
| Soares, L | 1 |
| Altschuler, E | 3 |
| Kim, P | 1 |
| Lyytikäinen, O | 1 |
| Elonen, E | 1 |
| Lautenschlager, I | 1 |
| Jokipii, A | 1 |
| Tiittanen, L | 1 |
| Ruutu, P | 1 |
| Riou, JF | 1 |
| Davey, RA | 1 |
| Su, GM | 1 |
| Hargrave, RM | 1 |
| Harvie, RM | 1 |
| Davey, MW | 1 |
| Ma, XJ | 1 |
| Xiang, YM | 1 |
| Hong, J | 1 |
| Laurençot, CM | 1 |
| Scheffer, GL | 1 |
| Scheper, RJ | 1 |
| Shoemaker, RH | 1 |
| Laroche-Clary, A | 1 |
| Larrue, A | 1 |
| Robert, J | 1 |
| Mitchell, MJ | 1 |
| Satitpunwaycha, P | 1 |
| Gieseler, F | 1 |
| Granzen, B | 1 |
| Graves, DE | 1 |
| Danks, MK | 2 |
| Beck, WT | 2 |
| Rappa, G | 1 |
| Lorico, A | 1 |
| Sartorelli, AC | 1 |
| Ehninger, G | 1 |
| Proksch, B | 1 |
| Wanner, T | 1 |
| Schuler, U | 1 |
| Busch, FW | 1 |
| Schmidt, H | 1 |
| Schleyer, E | 1 |
| Jaschonek, K | 1 |
| Hiddemann, W | 2 |
| Chan, D | 3 |
| Richel, DJ | 1 |
| Colly, LP | 1 |
| Kluin-Nelemans, JC | 1 |
| Willemze, R | 2 |
| Feldman, EJ | 1 |
| Ahmed, T | 3 |
| Puccio, C | 1 |
| Chun, HG | 1 |
| Cook, P | 1 |
| Baskind, P | 2 |
| Marboe, C | 1 |
| Mehta, R | 3 |
| Snow, K | 1 |
| Judd, W | 1 |
| Fernandes, DJ | 1 |
| Marit, G | 1 |
| Cony, P | 1 |
| Duclos, F | 1 |
| Puntous, M | 1 |
| Broustet, A | 1 |
| Reiffers, J | 1 |
| Cunningham, M | 1 |
| Hanauske, AR | 2 |
| Hanauske, U | 1 |
| Von Hoff, DD | 2 |
| Spiers, A | 2 |
| Knospe, WH | 2 |
| Soojian, M | 1 |
| Brons, PP | 1 |
| Wessels, JM | 1 |
| Linssen, PC | 1 |
| Haanen, C | 2 |
| Speth, PA | 1 |
| Jehn, U | 3 |
| Estey, E | 2 |
| Bakic, M | 2 |
| Silberman, L | 2 |
| Andersson, BS | 3 |
| Beran, M | 3 |
| Ricketts, L | 1 |
| Maschmeyer, G | 1 |
| Kreutzmann, H | 1 |
| Wendt, F | 1 |
| Adelstein, DJ | 2 |
| Keller, A | 2 |
| O'Connell, MJ | 2 |
| Petti, MC | 1 |
| Avvisati, G | 1 |
| Tafuri, A | 1 |
| Meloni, G | 1 |
| Amadori, S | 1 |
| Mandelli, F | 1 |
| Liang, R | 1 |
| Chan, TK | 1 |
| Todd, D | 1 |
| Dhaliwal, HS | 1 |
| Shannon, MS | 1 |
| Barnett, MJ | 1 |
| Prentice, HG | 1 |
| Bragman, K | 1 |
| Malpas, JS | 1 |
| Lister, TA | 1 |
| Posada, JG | 1 |
| Hess, F | 1 |
| Ross, BJ | 1 |
| Feldman, E | 2 |
| Weinstein, P | 1 |
| Rieber, E | 2 |
| Sullivan, P | 2 |
| Van Mouwerik, TJ | 1 |
| Caines, PM | 1 |
| Ballentine, R | 1 |
| Kantarjian, HM | 1 |
| Arlin, Z | 1 |
| Pucillo, A | 1 |
| Tallman, MS | 1 |
| Appelbaum, FR | 1 |
| Amos, D | 1 |
| Goldberg, RS | 1 |
| Livingston, RB | 1 |
| Mortimer, J | 1 |
| Weiden, PL | 1 |
| Thomas, ED | 1 |
| Stuckey, SE | 1 |
| Mavligit, GM | 1 |
| Schiffer, CA | 1 |
| Davis, RB | 1 |
| Mayer, RJ | 1 |
| Peterson, BA | 1 |
| Lee, EJ | 1 |
| Dekker, AW | 1 |
| Punt, K | 1 |
| Verdonck, LF | 1 |
| Paul, CY | 1 |
| Liliemark, JO | 1 |
| Farmen, RH | 1 |
| Franks, CR | 1 |
| Uytdenhoef, M | 1 |
| Peterson, CO | 1 |
| Lindpaintner, K | 1 |
| Lindpaintner, LS | 1 |
| Wentworth, M | 1 |
| Burns, CP | 1 |
| Abrams, RA | 1 |
| Hanson, G | 1 |
| Hansen, RM | 1 |
| Anderson, T | 1 |
| Odaimi, M | 1 |
| Wilson, WR | 1 |
| Keating, M | 1 |
| Begg, CB | 1 |
| Silber, R | 1 |
| Burkart, PT | 1 |
| Scharfman, W | 1 |
| Letendre, L | 1 |
| Hinemann, V | 1 |
| Hoagland, HC | 1 |
| Kovach, JS | 1 |
| Gaddipati, J | 1 |
| Friedland, M | 1 |
| Zittoun, R | 2 |
| Bury, J | 1 |
| Stryckmans, P | 1 |
| Lowenberg, B | 1 |
| Peetermans, M | 1 |
| Rozendaal, KY | 1 |
| Kerkhofs, M | 1 |
| Louie, AC | 1 |
| Issell, BF | 1 |
| Edelstein, M | 1 |
| Valeriote, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pilot, Pharmacodynamic Correlate Trial of Sirolimus in Combination With Chemotherapy (Idarubicin, Cytarabine) for the Treatment of Newly Diagnosed Acute Myelogenous Leukemia[NCT01822015] | Early Phase 1 | 55 participants (Actual) | Interventional | 2013-03-15 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
13 reviews available for amsacrine and Leukemia
| Article | Year |
|---|---|
The FLAMSA concept-past and future.
Topics: Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Foreca | 2020 |
Treatment of acute leukemia--advances in chemotherapy, immunotherapy, and bone marrow transplantation.
Topics: Aclarubicin; Acute Disease; Adolescent; Adult; Age Factors; Aminoacridines; Amsacrine; Anthraquinone | 1983 |
Current status of amsacrine (AMSA) combination chemotherapy programs in acute leukemia.
Topics: Acute Disease; Aminoacridines; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Clinical T | 1983 |
New cytotoxic drugs for breast cancer and their clinical evaluation.
Topics: Altretamine; Aminoacridines; Amsacrine; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as | 1980 |
Nonhematologic toxicities of selected chemotherapeutic agents used in the treatment of adult leukemia.
Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; | 1990 |
The human tumor cloning assay in cancer research and therapy: a review with clinical correlations.
Topics: Aminoacridines; Amsacrine; Animals; Anthracenes; Antineoplastic Agents; Blood Physiological Phenomen | 1985 |
Topoisomerase II as a target of antileukemia drugs: a review of controversial areas.
Topics: Amsacrine; Antineoplastic Agents; DNA; DNA Topoisomerases, Type II; Humans; Leukemia | 1989 |
New drugs in the treatment of acute and chronic leukaemia: current role of mAMSA.
Topics: Acute Disease; Adult; Amsacrine; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemothera | 1989 |
New strategies in the management of acute leukemias.
Topics: Acute Disease; Amsacrine; Aneuploidy; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Pr | 1987 |
Amsacrine (AMSA)--a clinical review.
Topics: Adult; Aminoacridines; Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoc | 1985 |
Cytosine arabinoside in experimental combination therapy.
Topics: Aminoacridines; Amsacrine; Animals; Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosyl | 1985 |
m-AMSA: a review of clinical data.
Topics: Acute Disease; Aminoacridines; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Drug Evalu | 1985 |
Clinical correlations with the human tumor cloning assay.
Topics: Aminoacridines; Amsacrine; Anthracenes; Breast Neoplasms; Clinical Trials as Topic; Clone Cells; Cul | 1985 |
14 trials available for amsacrine and Leukemia
| Article | Year |
|---|---|
[Phase III clinical trial on domestic amsacrine in patients with acute leukemias].
Topics: Adolescent; Adult; Aged; Amsacrine; Child; Child, Preschool; Female; Humans; Leukemia; Male; Middle | 1997 |
Current status of amsacrine (AMSA) combination chemotherapy programs in acute leukemia.
Topics: Acute Disease; Aminoacridines; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Clinical T | 1983 |
New cytotoxic drugs for breast cancer and their clinical evaluation.
Topics: Altretamine; Aminoacridines; Amsacrine; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as | 1980 |
Evaluation of AMSA in children with acute leukemia. A Pediatric Oncology Group study.
Topics: Acute Disease; Adolescent; Aminoacridines; Amsacrine; Antineoplastic Agents; Child; Drug Administrat | 1984 |
High-dose AMSA and autologous bone marrow transplantation in relapsed acute leukemia.
Topics: Acute Disease; Adult; Aminoacridines; Amsacrine; Antineoplastic Agents; Bone Marrow Transplantation; | 1982 |
m-AMSA: an exciting new drug in the National Cancer Institute Drug Development Program.
Topics: Acute Disease; Aminoacridines; Amsacrine; Breast Neoplasms; Clinical Trials as Topic; Dose-Response | 1980 |
AMSA--a promising new agent in refractory acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Aminoacridines; Amsacrine; Antineoplastic Agents; Child; Cli | 1982 |
Amsacrine-associated cardiotoxicity: an analysis of 82 cases.
Topics: Adolescent; Aminoacridines; Amsacrine; Antineoplastic Agents; Arrhythmias, Cardiac; Cardiomyopathies | 1986 |
A new regimen of amsacrine with high-dose cytarabine is safe and effective therapy for acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; B | 1987 |
Amsacrine evaluation.
Topics: Adult; Amsacrine; Child; Clinical Trials as Topic; Humans; Kinetics; Leukemia; Neoplasms | 1987 |
A strategy for evaluation of new treatments in untreated patients: application to a clinical trial of AMSA for acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; C | 1987 |
Effect of amsacrine on ara-CTP cellular pharmacology in human leukemia cells during high-dose cytarabine therapy.
Topics: Acute Disease; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Arabinofurano | 1987 |
Amsacrine (AMSA)--a clinical review.
Topics: Adult; Aminoacridines; Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoc | 1985 |
Clinical correlations with the human tumor cloning assay.
Topics: Aminoacridines; Amsacrine; Anthracenes; Breast Neoplasms; Clinical Trials as Topic; Clone Cells; Cul | 1985 |
77 other studies available for amsacrine and Leukemia
| Article | Year |
|---|---|
Structure-activity relationships for acridine-substituted analogues of the mixed topoisomerase I/II inhibitor N-[2-(dimethylamino)ethyl]acridine-4-carboxamide.
Topics: Acridines; Animals; Antineoplastic Agents; Cell Division; Colonic Neoplasms; Enzyme Inhibitors; Leuk | 1997 |
Amsacrine suppresses matrix metalloproteinase-2 (MMP-2)/MMP-9 expression in human leukemia cells.
Topics: Amsacrine; Down-Regulation; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Humans; Leuke | 2014 |
Treatment-subgroup interaction: an example from a published, phase II clinical trial.
Topics: Acute Disease; Adult; Amsacrine; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocol | 2009 |
Stem cell transplantation after salvage therapy with high-dose cytarabine and amsacrine in adults with high-risk leukaemia.
Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; He | 2003 |
Usefulness of PKH fluorescent labelling to study leukemic cell proliferation with various cytostatic drugs or acetyl tetrapeptide--AcSDKP.
Topics: Amsacrine; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Br | 2005 |
Zygomycosis in the immunocompromised patient: a case report.
Topics: Absidia; Acute Disease; Aerosols; Amphotericin B; Amsacrine; Antibiotic Prophylaxis; Antifungal Agen | 2006 |
Amsacrine and 5-azacytidine in acute non lymphatic leukaemia (ANLL).
Topics: Acute Disease; Adult; Aminoacridines; Amsacrine; Azacitidine; Humans; Leukemia | 1982 |
Combination chemotherapy with amsacrine (AMSA) and cyclocytidine in refractory childhood leukemia: preliminary observations of a phase II study.
Topics: Adolescent; Aminoacridines; Amsacrine; Ancitabine; Antineoplastic Agents; Child; Child, Preschool; C | 1983 |
4'-(9-acridinylamino)methane-sulfon-m-anisidide (m-AMSA) and 5-azacytidine (AZA) in the treatment of relapsed adult acute leukemia.
Topics: Acute Disease; Adult; Aged; Aminoacridines; Amsacrine; Antineoplastic Agents; Azacitidine; Drug Ther | 1983 |
High-dose cytosine arabinoside and m-AMSA is effective therapy in relapsed acute nonlymphocytic leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Aminoacridines; Amsacrine; Antineoplastic Combined Chemother | 1984 |
Acridinyl anisidide (m-AMSA) therapy in 11 patients with refractory acute leukemia.
Topics: Adolescent; Adult; Aminoacridines; Amsacrine; Bone Marrow; Cytarabine; Drug Evaluation; Drug Therapy | 1984 |
High-dose amsacrine (AMSA) therapy of relapsed and refractory adult acute nonlymphocytic leukemia. A phase II study.
Topics: Acute Disease; Adult; Aged; Aminoacridines; Amsacrine; Antineoplastic Agents; Drug Administration Sc | 1984 |
Phase II study of amsacrine gluconate in refractory leukemia.
Topics: Adult; Aged; Aminoacridines; Amsacrine; Drug Evaluation; Female; Gluconates; Humans; Lactates; Leuke | 1983 |
Prediction of complete remission in patients with refractory acute leukemia treated with AMSA.
Topics: Acute Disease; Adult; Aminoacridines; Amsacrine; Female; Humans; Leukemia; Leukemia, Lymphoid; Leuke | 1984 |
m-AMSA: phase II trial in advanced lymphoma and leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Aminoacridines; Amsacrine; Antineoplastic Agents; Bone Marro | 1984 |
Acute electrocardiographic changes induced by amsacrine.
Topics: Acute Disease; Adolescent; Adult; Aminoacridines; Amsacrine; Antineoplastic Agents; Antineoplastic C | 1984 |
AMSA-induced seizures in patients with hypokalemia.
Topics: Aminoacridines; Amsacrine; Female; Humans; Hypokalemia; Leukemia; Middle Aged; Seizures | 1983 |
Laboratory-designed drug used against leukemia.
Topics: Adult; Aminoacridines; Amsacrine; Antineoplastic Agents; Drug Therapy, Combination; Humans; Leukemia | 1980 |
Phase I study of m-AMSA in patients with solid tumors and leukemias.
Topics: Acute Disease; Adolescent; Adult; Aged; Aminoacridines; Amsacrine; Chemical and Drug Induced Liver I | 1980 |
Treatment of acute leukemia in relapse with 4'(9-acridinylamino) methanesulfon-m-anisidide (AMSA) in combination with cytosine arabinoside and thioguanine.
Topics: Acute Disease; Adolescent; Adult; Aged; Aminoacridines; Amsacrine; Antineoplastic Agents; Chemical a | 1981 |
Phase II study of 4'-(9-acridinylamino)methanesulfon-m-anisidide (NSC 249992) in children with acute leukemia and lymphoma.
Topics: Acute Disease; Adolescent; Aminoacridines; Amsacrine; Antineoplastic Agents; Child; Child, Preschool | 1982 |
AMSA toxicity in patients with abnormal liver function.
Topics: Adult; Aged; Aminoacridines; Amsacrine; Antineoplastic Agents; Dose-Response Relationship, Drug; Hum | 1981 |
In vitro chemosensitivities of human tumor stem cells to the Phase II drug 4'-(9-acridinylamino)methanesulfon-m-anisidide and prospective in vivo correlations.
Topics: Aminoacridines; Amsacrine; Antineoplastic Agents; Cells, Cultured; Drug Evaluation; Female; Genital | 1982 |
[Phase I-II studies of a new antineoplastic agent, 4'-(9-acridinylamino)-methanesulfon-m-anisidide (AMSA)].
Topics: Adult; Aged; Aminoacridines; Amsacrine; Antineoplastic Agents; Breast Neoplasms; Drug Evaluation; Fe | 1982 |
Phase I and II trial of 4'-(9-acridinylamino)methanesulfon-m-anisidide in patients with acute leukemia.
Topics: Adolescent; Adult; Aminoacridines; Amsacrine; Drug Administration Schedule; Drug Evaluation; Humans; | 1980 |
Evaluation of AMSA in previously treated patients with acute leukemia: results of therapy in 109 adults.
Topics: Acute Disease; Aminoacridines; Amsacrine; Antineoplastic Agents; Dose-Response Relationship, Drug; H | 1982 |
Successful treatment of a patient with acute nonlymphoblastic leukemia (ANLL) and anthracycline cardiomyopathy with 4' (9-acridinylamino) methanesulfon-m-anisidide (AMSA).
Topics: Acute Disease; Adult; Aminoacridines; Amsacrine; Antibiotics, Antineoplastic; Antineoplastic Agents; | 1982 |
Current status of clinical trials of m-AMSA, dihydroxyanthracenedione, and deoxycoformycin.
Topics: Adenosine Deaminase Inhibitors; Aminoacridines; Amsacrine; Anthracenes; Antineoplastic Agents; Cofor | 1982 |
Drug-sensitivity and DNA-binding of a subform of topoisomerase II alpha in resistant human HL-60 cells.
Topics: Amsacrine; Antigens, Neoplasm; Antineoplastic Agents; DNA Topoisomerases, Type II; DNA-Binding Prote | 1994 |
Quantification of topoisomerase-DNA complexes in leukemia cells from patients undergoing therapy with a topoisomerase-directed agent.
Topics: Amsacrine; Antineoplastic Agents; Camptothecin; DNA Probes; DNA Topoisomerases, Type I; DNA Topoisom | 1994 |
Further characterization of an amsacrine-resistant line of HL-60 human leukemia cells and its topoisomerase II. Effects of ATP concentration, anion concentration, and the three-dimensional structure of the DNA target.
Topics: Adenosine Triphosphate; Amsacrine; Anions; Catalysis; DNA; DNA Damage; DNA Topoisomerases, Type II; | 1993 |
Pneumocystis carinii pneumonia in adults with acute leukaemia: is there a need for primary chemoprophylaxis?
Topics: Aclarubicin; Acute Disease; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Carmus | 1996 |
From amsacrine to DACA (N-[2-(dimethylamino)ethyl]acridine-4-carboxamide): selectivity for topoisomerases I and II among acridine derivatives.
Topics: Acridines; Amsacrine; Antineoplastic Agents; DNA; DNA Damage; DNA Topoisomerases, Type I; DNA Topois | 1996 |
The potential of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide to circumvent three multidrug-resistance phenotypes in vitro.
Topics: Acridines; Amsacrine; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1 | 1997 |
[Venous protection of acute leukemia treatment with amsacrine].
Topics: Acute Disease; Amsacrine; Antineoplastic Agents; Fluid Therapy; Humans; Leukemia; Phlebitis | 1996 |
Increased LRP mRNA expression is associated with the MDR phenotype in intrinsically resistant human cancer cell lines.
Topics: Amsacrine; Antineoplastic Agents; ATP-Binding Cassette Transporters; Cell Nucleus; Cisplatin; Coloni | 1997 |
Down-regulation of bcr-abl and bcl-x(L) expression in a leukemia cell line and its doxorubicin-resistant variant by topoisomerase II inhibitors.
Topics: Amsacrine; Antineoplastic Agents; Apoptosis; bcl-X Protein; Chromatography, High Pressure Liquid; Do | 2000 |
Relative activity of structural analogues of amsacrine against human leukemia cell lines containing amsacrine-sensitive or -resistant forms of topoisomerase II: use of computer simulations in new drug development.
Topics: Amsacrine; Benzenesulfonamides; Carbamates; Computer Simulation; DNA Topoisomerases, Type I; DNA Top | 1992 |
The measurement of nuclear topoisomerase II inhibition in vitro: a possible tool for detecting resistance on a subcellular level in haematopoietic malignancies.
Topics: Amsacrine; Antineoplastic Agents; Cell Nucleus; Drug Resistance; Etoposide; Humans; In Vitro Techniq | 1992 |
Structure-activity studies of amsacrine analogs in drug resistant human leukemia cell lines expressing either altered DNA topoisomerase II or P-glycoprotein.
Topics: Amsacrine; ATP Binding Cassette Transporter, Subfamily B, Member 1; Base Sequence; Cell Division; DN | 1992 |
Potentiation by novobiocin of the cytotoxic activity of etoposide (VP-16) and teniposide (VM-26).
Topics: Adenocarcinoma; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cell Survival; DNA; DNA T | 1992 |
Intracellular cytosine arabinoside accumulation and cytosine arabinoside triphosphate formation in leukemic blast cells is inhibited by etoposide and teniposide.
Topics: Acute Disease; Adult; Aged; Amsacrine; Arabinofuranosylcytosine Triphosphate; Cytarabine; Drug Inter | 1992 |
The effect of staurosporine on drug-induced, topoisomerase II-mediated DNA cleavage in human leukemia cells.
Topics: Alkaloids; Amsacrine; Cell Line; DNA Damage; DNA Topoisomerases, Type II; DNA, Neoplasm; Dose-Respon | 1991 |
The antileukaemic activity of 5-Aza-2 deoxycytidine (Aza-dC) in patients with relapsed and resistant leukaemia.
Topics: Acute Disease; Adult; Amsacrine; Antigens, CD; Antineoplastic Agents; Antineoplastic Combined Chemot | 1991 |
Amsacrine is safe and effective therapy for patients with myocardial dysfunction and acute leukemia.
Topics: Amsacrine; Cardiac Output, Low; Cytarabine; Drug Therapy, Combination; Humans; Leukemia; Leukemia, M | 1991 |
Multiple patterns of resistance of human leukemia cell sublines to amsacrine analogues.
Topics: Amsacrine; Drug Resistance; Humans; Leukemia; Structure-Activity Relationship; Topoisomerase II Inhi | 1990 |
Decreased nuclear matrix DNA topoisomerase II in human leukemia cells resistant to VM-26 and m-AMSA.
Topics: Amsacrine; Animals; Antineoplastic Agents; Cell Nucleus; Crithidia; DNA; DNA Topoisomerases, Type II | 1990 |
Treatment of relapsed or refractory acute leukemia: comparison of two different regimens.
Topics: Acute Disease; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transpl | 1990 |
Amsacrine [4'-(9-acridinylamino)-methanesulfon-m-anisidide] (m-AMSA) and 5-azacytidine (AZA) for remission reinduction in patients with relapsed adult acute nonlymphocytic leukemia. An ECOG pilot study. Eastern Cooperative Oncology Group.
Topics: Acute Disease; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; | 1987 |
Determination of amsacrine in human nucleated hematopoietic cells.
Topics: Amsacrine; Chromatography, High Pressure Liquid; Dextrans; Hematopoietic System; Humans; Leukemia; L | 1987 |
Topoisomerase II as a target of antileukemic drugs.
Topics: Amsacrine; Animals; DNA Topoisomerases, Type II; Drug Resistance; Humans; Leukemia; Leukemia, Experi | 1987 |
Effect of 1-beta-D-arabinofuranosylcytosine (ara-C) on nuclear topoisomerase II activity and on the DNA cleavage and cytotoxicity produced by 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA) and etoposide in m-AMSA-sensitive and -resistant human le
Topics: Amsacrine; Cell Division; Cell Nucleus; Cytarabine; DNA; DNA Topoisomerases, Type II; Drug Resistanc | 1987 |
Combined chemotherapy with m-amsacrine in high-risk patients with acute non-lymphocytic leukemia.
Topics: Acute Disease; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; E | 1987 |
Prolonged survival after high-dose cytosine arabinoside and amsacrine induction in patients with previously untreated de novo acute nonlymphocytic leukemia.
Topics: Acute Disease; Amsacrine; Bone Marrow Transplantation; Cytarabine; Dose-Response Relationship, Drug; | 1987 |
Sequential pilot studies of intensive postremission chemotherapy for acute nonlymphocytic leukemia.
Topics: Acute Disease; Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Ma | 1987 |
Chemotherapy for relapsed and resistant acute nonlymphoblastic leukemia. Effect of ATA, an amsacrine-containing regime.
Topics: Acute Disease; Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; C | 1988 |
Treatment of acute leukaemia with m-AMSA in combination with cytosine arabinoside.
Topics: Aged; Amsacrine; Chemical and Drug Induced Liver Injury; Cytarabine; Female; Gastrointestinal Diseas | 1986 |
Amsacrine treatment of patients with supraventricular arrhythmias and acute leukemia.
Topics: Acute Disease; Aged; Amsacrine; Arrhythmia, Sinus; Atrial Fibrillation; Female; Humans; Leukemia; Mi | 1987 |
Evaluation of intensive postremission chemotherapy for adults with acute nonlymphocytic leukemia using high-dose cytosine arabinoside with L-asparaginase and amsacrine with etoposide.
Topics: Acute Disease; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; | 1987 |
Sensitivity and resistance to chemotherapy in acute leukemia: correlation with in vitro drug uptake and lack of potentiation by verapamil.
Topics: Acute Disease; Adult; Aged; Amsacrine; Cells, Cultured; Doxorubicin; Drug Resistance; Drug Synergism | 1987 |
Combination chemotherapy with diaziquone and amsacrine in relapsed and refractory acute nonlymphocytic leukemia: a Cancer and Leukemia Group B Study.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Amsacrine; Antineoplastic Agents; Aziridi | 1987 |
The use of amsacrine plus intermediate-dose cytosine arabinoside in relapsed and refractory acute nonlymphocytic leukemia.
Topics: Acute Disease; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Leukem | 1987 |
Comparison of the pharmacokinetics of AMSA and AMSA-lactate in patients with acute nonlymphoblastic leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Amsacrine; Female; Humans; Lactates; Lactic Acid; Leukemia; | 1987 |
Acute myocardial necrosis during administration of amsacrine.
Topics: Aminoacridines; Amsacrine; Antineoplastic Agents; Electrocardiography; Female; Humans; Leukemia; Mid | 1986 |
Phase II study of combination chemotherapy with etoposide and amsacrine in relapsed adult leukemia.
Topics: Adult; Aged; Aminoacridines; Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 1986 |
[A new drug and current strategy in the treatment of acute non-lymphocytic leukemia in adults].
Topics: Acute Disease; Adult; Aminoacridines; Amsacrine; Anthraquinones; Antineoplastic Agents; Cytarabine; | 1986 |
Drug sensitivity and cross-resistance of the 4'-(9-acridinylamino)methanesulfon-m-anisidide-resistant subline of HL-60 human leukemia.
Topics: Aminoacridines; Amsacrine; Cell Line; Cell Survival; Cytarabine; Doxorubicin; Drug Resistance; Etopo | 1986 |
Comparison of in vitro activity of cytotoxic drugs towards human carcinoma and leukaemia cell lines.
Topics: Aminoacridines; Amsacrine; Antineoplastic Agents; Cell Count; Cell Line; Cell Survival; Colonic Neop | 1986 |
Effect of m-AMSA on the cellular pharmacology of ara-CTP in human leukemic cells during therapy with high-dose ara-C.
Topics: Amsacrine; Arabinofuranosylcytosine Triphosphate; Arabinonucleotides; Cytarabine; Dose-Response Rela | 1986 |
Prolonged unmaintained remission after intensive consolidation therapy in adult acute nonlymphocytic leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; B | 1987 |
Combination amsacrine and high-dose cytosine arabinoside in acute leukemia.
Topics: Aminoacridines; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Leuke | 1985 |
Amsacrine: a new drug for hematological malignancies.
Topics: Aminoacridines; Amsacrine; Antineoplastic Agents; Humans; Intercalating Agents; Leukemia; Lymphoma | 1985 |
Phase I study of VP-16 (etoposide) and amsacrine (AMSA) in the treatment of refractory acute leukemia.
Topics: Acute Disease; Adult; Aged; Aminoacridines; Amsacrine; Antineoplastic Agents; Antineoplastic Combine | 1985 |
High-dose cytosine arabinoside and mAMSA induction and consolidation in patients with previously untreated de novo acute nonlymphocytic leukemia: Phase I Pilot Study for the Eastern Cooperative Oncology Group.
Topics: Aminoacridines; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; | 1985 |
Treatment of acute leukemia with amsacrine and high-dose cytarabine.
Topics: Acute Disease; Aminoacridines; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine | 1985 |
Amsacrine with high-dose cytarabine in acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Aminoacridines; Amsacrine; Antineoplastic Combined Chemother | 1985 |
[Experiences with HD-Ara C treatment in leukemia patients].
Topics: Acute Disease; Aminoacridines; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine | 1985 |